Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q4 2013 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$2.10M-$2.10MderivedN/M vs Q4 2012 EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$2,097,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,130,000N/M ended Dec 31, 2013 · filed Mar 20, 2014 · 79 d after period end